Information Provided By: 
Fly News Breaks for August 6, 2018
WELL, SFTBY, ALDR, SAGE, GBT
Aug 6, 2018 | 10:17 EDT
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Global Blood Therapeutics (GBT) initiated with an Overweight at Piper Jaffray. 2. Welltower (WELL) reinstated with a Neutral at Goldman Sachs. 3. Sage Therapeutics (SAGE) initiated with an Overweight at Piper Jaffray. 4. SoftBank (SFTBY) initiated with a Buy at UBS. 5. Alder Biopharmaceuticals (ALDR) initiated with an Overweight at Piper Jaffray. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
News For GBT;SAGE;ALDR;SFTBY;WELL From the Last 2 Days
SAGE
Apr 26, 2024 | 08:21 EDT
SAGE
Apr 26, 2024 | 07:58 EDT
RBC Capital lowered the firm's price target on Sage Therapeutics (SAGE) to $15 from $26 and keeps a Sector Perform rating on the shares after its Q1 earnings miss. The analyst also cites the company's limited additional detail on Zurzuvae launch relative to what was already provided by partner Biogen (BIIB), other than some prescription metrics. Sage's pipeline remains high-risk, though dalzanemdor may still have some shot in Huntington's Disease despite the recent Parkinson's Disease failure, the firm tells investors in a research note.
SAGE
Apr 26, 2024 | 07:50 EDT
SAGE
Apr 26, 2024 | 06:46 EDT
SAGE
Apr 25, 2024 | 14:16 EDT
SAGE
Apr 25, 2024 | 11:12 EDT
